Study Type
Interventional - Drug
The objective of the REMIT-iGarLixi study is to determine if, in patients with recently diagnosed T2DM, a 12-week course of iGlarLixi (combined basal insulin glargine and lixisenatide), metformin, and lifestyle approaches will achieve drug-free diabetes remission in a higher proportion of patients than standard diabetes therapy at 24 weeks (three months after the drugs are stopped).
Participants will be randomized to two treatment groups:
The primary outcome in this trial will be diabetes remission evaluated at 24 weeks after randomization.
Interventional - Drug
A multicentre, open-label, randomized controlled trial
1
8
161
2017-2020
PHRI
Back To Top